



JAPANESE  
INDUSTRIAL  
STANDARD

Translated and Published by  
Japanese Standards Association

---

---

JIS K 0312 : 2008

**Method for determination of tetra-through  
octachlorodibenzo-p-dioxins,  
tetra-through octachlorodibenzofurans  
and dioxin-like polychlorinatedbiphenyls  
in industrial water and waste water  
(Amendment 1)**

JIS K 0312 : 2005 has been revised under date of January 20, 2008. The revised items are included in this Amendment 1 and use this in combination with JIS K 0312 : 2005.

---

ICS 13.060.25;13.060.30

Reference number : JIS K 0312 : 2008 (E)

PROTECTED BY COPYRIGHT  
Provided by IHS

 **Documents**  
Document Sharing Hub  
6 S

## Foreword

This translation has been made based on the original Japanese Industrial Standard revised by the Minister of Economy, Trade and Industry through deliberations at the Japanese Industrial Standards Committee in accordance with the Industrial Standardization Law.

Consequently, JIS K 0312:2005 is partially replaced with this Amendment.

Date of Establishment: 1999-09-20

Date of Revision: 2008-01-20

Date of Public Notice in Official Gazette: 2008-01-21

Investigated by: Japanese Industrial Standards Committee  
Standards Board

Technical Committee on Environment and Recycling Policy

---

JIS K 0312: 2008, First English edition published in 2008-03

Translated and published by: Japanese Standards Association  
4-1-24, Akasaka, Minato-ku, Tokyo, 107-8440 JAPAN

---

In the event of any doubts arising as to the contents,  
the original JIS is to be the final authority.

© JSA 2008

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from the publisher.

Printed in Japan

KA/SW

# Method for determination of tetra-through octachlorodibenzo-p-dioxins, tetra-through octachlorodibenzofurans and dioxin-like polychlorinatedbiphenyls in industrial water and waste water (Amendment 1)

JIS K 0312 : 2005 is revised as follows.

This revision applies from April 1st, 2008.

## 8.3 Change to toxicity equivalency (TEQ)

In table 9, replace

"

| Compounds                      |                              | TEF (1998)* |
|--------------------------------|------------------------------|-------------|
| PCDDs                          | 2,3,7,8-TeCDD                | 1           |
|                                | 1,2,3,7,8-PeCDD              | 1           |
|                                | 1,2,3,4,7,8-HxCDD            | 0.1         |
|                                | 1,2,3,6,7,8-HxCDD            | 0.1         |
|                                | 1,2,3,7,8,9-HxCDD            | 0.1         |
|                                | 1,2,3,4,6,7,8-HpCDD          | 0.01        |
|                                | 1,2,3,4,6,7,8,9-OCDD         | 0.000 1     |
|                                | Others                       | 0           |
| PCDFs                          | 2,3,7,8-TeCDF                | 0.1         |
|                                | 1,2,3,7,8-PeCDF              | 0.05        |
|                                | 2,3,4,7,8-PeCDF              | 0.5         |
|                                | 1,2,3,4,7,8-HxCDF            | 0.1         |
|                                | 1,2,3,6,7,8-HxCDF            | 0.1         |
|                                | 1,2,3,7,8,9-HxCDF            | 0.1         |
|                                | 2,3,4,6,7,8-HxCDF            | 0.1         |
|                                | 1,2,3,4,6,7,8-HpCDF          | 0.01        |
|                                | 1,2,3,4,7,8,9-HpCDF          | 0.01        |
|                                | 1,2,3,4,6,7,8,9-OCDF         | 0.000 1     |
|                                | Others                       | 0           |
| DL-PCB<br>Non-ortho compounds  | 3,4,4',5'-TeCB (#81)         | 0.000 1     |
|                                | 3,3',4,4'-TeCB (#77)         | 0.000 1     |
|                                | 3,3',4,4',5'-PeCB (#126)     | 0.1         |
|                                | 3,3',4,4',5,5'-HxCB (#169)   | 0.01        |
| DL-PCB<br>Mono-ortho compounds | 2',3,4,4',5'-PeCB (#123)     | 0.000 1     |
|                                | 2,3',4,4',5'-PeCB (#118)     | 0.000 1     |
|                                | 2,3,3',4,4'-PeCB (#105)      | 0.000 1     |
|                                | 2,3,4,4',5'-PeCB (#114)      | 0.000 5     |
|                                | 2,3',4,4',5,5'-HxCB (#167)   | 0.000 01    |
|                                | 2,3,3',4,4',5'-HxCB (#156)   | 0.000 5     |
|                                | 2,3,3',4,4',5'-HxCB (#157)   | 0.000 5     |
|                                | 2,3,3',4,4',5,5'-HpCB (#189) | 0.000 1     |

NOTE \* TEF refers to the proposal of WHO/IPCS in 1998."

by

"

| Compounds                      |                              | TEF (2006)* |
|--------------------------------|------------------------------|-------------|
| PCDDs                          | 2,3,7,8-TeCDD                | 1           |
|                                | 1,2,3,7,8-PeCDD              | 1           |
|                                | 1,2,3,4,7,8-HxCDD            | 0.1         |
|                                | 1,2,3,6,7,8-HxCDD            | 0.1         |
|                                | 1,2,3,7,8,9-HxCDD            | 0.1         |
|                                | 1,2,3,4,6,7,8-HpCDD          | 0.01        |
|                                | 1,2,3,4,6,7,8,9-OCDD         | 0.000 3     |
|                                | Others                       | 0           |
| PCDFs                          | 2,3,7,8-TeCDF                | 0.1         |
|                                | 1,2,3,7,8-PeCDF              | 0.03        |
|                                | 2,3,4,7,8-PeCDF              | 0.3         |
|                                | 1,2,3,4,7,8-HxCDF            | 0.1         |
|                                | 1,2,3,6,7,8-HxCDF            | 0.1         |
|                                | 1,2,3,7,8,9-HxCDF            | 0.1         |
|                                | 2,3,4,6,7,8-HxCDF            | 0.1         |
|                                | 1,2,3,4,6,7,8-HpCDF          | 0.01        |
|                                | 1,2,3,4,7,8,9-HpCDF          | 0.01        |
|                                | 1,2,3,4,6,7,8,9-OCDF         | 0.000 3     |
|                                | Others                       | 0           |
| DL-PCB<br>Non-ortho compounds  | 3,4,4',5'-TeCB (#81)         | 0.000 3     |
|                                | 3,3',4,4'-TeCB (#77)         | 0.000 1     |
|                                | 3,3',4,4',5'-PeCB (#126)     | 0.1         |
|                                | 3,3',4,4',5,5'-HxCB (#169)   | 0.03        |
| DL-PCB<br>Mono-ortho compounds | 2',3,4,4',5'-PeCB (#123)     | 0.000 03    |
|                                | 2,3',4,4',5'-PeCB (#118)     | 0.000 03    |
|                                | 2,3,3',4,4'-PeCB (#105)      | 0.000 03    |
|                                | 2,3,4,4',5'-PeCB (#114)      | 0.000 03    |
|                                | 2,3',4,4',5,5'-HxCB (#167)   | 0.000 03    |
|                                | 2,3,3',4,4',5'-HxCB (#156)   | 0.000 03    |
|                                | 2,3,3',4,4',5'-HxCB (#157)   | 0.000 03    |
|                                | 2,3,3',4,4',5,5'-HpCB (#189) | 0.000 03    |
|                                |                              |             |

NOTE \* TEF refers to the proposal by WHO/IPCS in 2005 and published in specialized magazine "Toxicological Science, Oxford Journal, Volume 93, Number 2 in 2006'."